Interaction Color Code
Clinical Bottom Line
Do not coadminister: Reduced levels of voriconazole
Drug 1
Drug 1 dose
400 mg Q12H x 9 days
Drug 1 effect
No significant change
Drug 2
Drug 2 dose
400 mg Q12H
Drug 2 effect
Voriconazole AUC decreased 83%; Cmax decreased 68%
Clinical Effects
Decreased voriconazole effects
Management
Do not coadminister with ritonavir or other ritonavir-boosted protease inhibitors unless benefit outweighs risks. If coadministering consider therapeutic drug monitoring.
Alternative Agents
Consider use of non-ritonavir containing antiretroviral regimens
Import ID
1087
